Acute tubulointerstitial nephritis in an HLA-B27-positive patient with axial spondyloarthritis being treated with adalimumab

Reumatol Clin (Engl Ed). 2019 May-Jun;15(3):179-181. doi: 10.1016/j.reuma.2017.03.012. Epub 2017 Jun 16.
[Article in English, Spanish]

Abstract

Antagonists of tumor necrosis factor-alpha (ATNF) are used for the treatment of multiple diseases such as psoriatic arthritis, Crohn's disease, ankylosing spondylitis and juvenile idiopathic arthritis, usually, when they are refractory to first-line treatment1. The use of ATNF has been associated with the induction of autoimmune diseases such as systemic lupus erythematosus-like disease, vasculitis, sarcoidosis-like diseases and, recently, acute granulomatous tubulointerstitial nephritis. We report a case of acute nongranulomatous tubulointerstitial nephritis in an HLA-B27-positive patient with axial spondyloarthritis and Crohn's disease being treated with adalimumab.

Keywords: Acute tubulointerstitial nephritis; Adalimumab; Antagonistas del factor de necrosis tumoral-alfa; Crohn's disease; Enfermedad de Crohn; Espondiloartritis; Nefritis túbulo-intersticial aguda; Spondyloarthritis; Tumor necrosis factor-alpha antagonists.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab / adverse effects*
  • Adalimumab / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Biopsy
  • Crohn Disease / complications
  • Crohn Disease / drug therapy
  • Disease Susceptibility
  • HLA-B27 Antigen
  • Humans
  • Kidney / pathology
  • Male
  • Middle Aged
  • Molecular Targeted Therapy
  • Nephritis, Interstitial / chemically induced*
  • Nephritis, Interstitial / drug therapy
  • Nephritis, Interstitial / pathology
  • Spondylarthritis
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antirheumatic Agents
  • HLA-B27 Antigen
  • Tumor Necrosis Factor-alpha
  • Adalimumab

Supplementary concepts

  • Acute Tubulointerstitial Nephritis